Search

The Bloodhound car will be a 1,000mph machine that is part spaceship, part jet fighter and part racing car. This is not a big vanity project but an engineering adventure designed to stir a new generation, says Mark Elvin

As the EU lays out some of its hoped-for outcomes from controversial EU-US trade talks in pharma, medical devices, energy and other fields, the European Ombudsman insists more transparency is needed

Science|Business makes some guesses at what research and innovation topics are likely to be among the most discussed in 2015.

Allowing academics to move their pensions from country-to-country when taking up jobs at institutions across the EU has broad support. But there is a swathe of technical and legal detail to sort out and universities need to sign up

ESADE will develop educational offerings specifically designed to strengthen the executive and leadership skills of digital entrepreneurs

A new drug for ovarian cancer, developed by researchers at the University of Cambridge and AstraZeneca, has become the first of new class of drugs, known as PARP-inhibitors, to be granted approval anywhere in the world. The drug, Lynparza, has been granted Marketing Authorisation from the European Commission.

Imperial has the greatest concentration of high impact research of any major UK university, according to the Research Excellence Framework (REF) 2014.

A total of 22 new companies were founded in 2014 by researchers from ETH Zurich. These spin-offs are among the most successful in Switzerland. One of the year's highlights was Covagen, which was acquired for over CHF 200 million. The latest figures also reveal that the university is on the right track with its promotion programmes.

To stay competitive in the global race to develop advanced manufacturing technologies, German industry must define and develop the digital framework for the “Internet of Things,” enabling everything from driverless cars to smart cities and e-health, a top official tells Science|Business

Portugal-based Gulbenkian Foundation will join an established research team, active in 11 African countries, to help fight rampant diseases like malaria and AIDS

Incessant talk of a North-South R&D divide is not baseless but it’s becoming tired. It is time to try and change things says Carlos Zorrinho, Brussels’ quiet revolutionary

Reform of the EU Emissions Trading System and review of genetically modified organisms and copyright laws on the slate for next year

The long-gestating Europe-wide patent, due to arrive at the start of 2015, is late. There remains uncertainty over the fees and the strength of the unified patent court, but EPO head Benoît Battistelli says don’t rush to judgement

Researchers at University of Bologna designed the first self-assembling molecular motor capable of converting light energy into work. The study was published in Nature Nanotechnology.

Three out of four Starting grants go to young researchers hosted by Germany, UK, France, the Netherlands, Israel and Spain. There are no grants going to Switzerland

China and the US set the pace on patent filings in 2013, while the number of patent applications received by the European Patent Office fell

Special emphasis was put on good usability in the selection process of the new research information management system.

ETH Zurich and the University of Zurich are founding a new translational research centre at the interface of medicine, science and engineering: the Wyss Translational Center Zurich. A USD 120 million donation from Dr. h.c. mult. Hansjörg Wyss to the two Zurich universities is making this possible. Through an interdisciplinary approach, the new centre aims to accelerate the development and application of innovative medical therapies and groundbreaking robotic systems.

For five years, robotics expert and Executive Board member Roland Siegwart has held the post of Vice President Research and Corporate Relations. He is now in the process of handing over this vice presidency to his successor, Detlef Günther, but he will always remain a firm fan of ETH Zurich.

A leading HIV expert at Imperial College London, Professor Weber has taken up his appointment as Director of the AHSC.